Physician profile
Michael C Marshall
NPI 1326026287
$10,639.37
in general payments reported to CMS, 2019-2025
55 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $349 · 2021: $283 · 2022: $1,860 · 2023: $2,180 · 2024: $2,512 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,887 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,887.32 |
| Education | $149.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,944.51 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,701.21 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,057.18 | 2019-2025 | Dupixent |
| Genzyme Corporation | $683.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.86 | 2019-2023 | Stiolto Respimat, Ofev |
| Insmed, INC. | $399.59 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $328.91 | 2019-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $304.28 | 2019-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $256.75 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $247.57 | 2022-2025 | Glassia, Hyqvia |
| Amgen INC. | $247.13 | 2022-2025 | Tezspire, Tavneos |
| Novartis Pharmaceuticals Corporation | $230.72 | 2019-2024 | |
| Electromed, INC. | $215.48 | 2022-2024 | Smartvest |
| Sunovion Pharmaceuticals INC. | $204.03 | 2019 | |
| Genentech USA, INC. | $202.40 | 2019-2022 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $185.70 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Bayer Healthcare Pharmaceuticals INC. | $182.92 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $147.90 | 2019-2025 | |
| Bioventus LLC | $141.46 | 2024 | Durolane |
| Csl Behring | $133.95 | 2022-2024 | Hizentra |
| Merck Sharp & Dohme LLC | $108.53 | 2019-2024 | Keytruda, Capvaxive |
| Janssen Pharmaceuticals, INC | $89.63 | 2020-2022 | |
| Pfizer INC. | $89.38 | 2019-2025 | |
| Boston Scientific Corporation | $87.74 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $81.61 | 2023-2025 | Lumryz |
| Verona Pharma, INC. | $75.43 | 2025 | Ohtuvayre |
| Philips North America LLC | $75.42 | 2022-2024 | (Ak6) Vest Therapy |
| Hospira, INC. | $74.70 | 2022-2023 | |
| Pulmonx Corporation | $58.96 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Axsome Therapeutics, INC. | $50.43 | 2023-2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $44.88 | 2022-2023 | Acthar |
| Resmed Corp | $43.78 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $42.04 | 2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $35.99 | 2025 | Yupelri |
| Harmony Biosciences LLC | $31.67 | 2023-2024 | Wakix |
| Melinta Therapeutics, LLC | $31.52 | 2019 | |
| Shionogi INC | $28.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.98 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $26.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.80 | 2019 | |
| Pharming Healthcare, INC. | $23.44 | 2022 | |
| Optinose US, INC. | $23.12 | 2024 | |
| Arbor Pharmaceuticals, INC. | $20.23 | 2021 | |
| Novo Nordisk INC | $19.53 | 2025 | Rybelsus, Ozempic |
| Shire North American Group INC | $17.72 | 2019 | |
| Vifor Pharma, INC. | $17.66 | 2024 | Veltassa |
| Paratek Pharmaceuticals, INC. | $16.86 | 2023 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $16.52 | 2025 | Alvesco |
| Liquidia Technologies, INC. | $16.45 | 2025 | Yutrepia |
| Portola Pharmaceuticals, LLC | $16.02 | 2020 | |
| Hikma Pharmaceuticals USA | $14.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2022 | |
| Astellas Pharma US INC | $13.83 | 2020 | |
| Angiodynamics, INC. | $13.12 | 2024 | Auryon Laser System 100-120 Vac |
| Phadia US INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.